APPENDIX I

ACCOUNTANTS’ REPORT

Attributable to BeiGene, Ltd.

Accumulated

Additional

Other

Paid-In
Capital

Comprehensive
Income/(loss)

Ordinary Shares

Shares

Amount

Accumulated

Deficit

Total

Non-

Controlling
Interests

Total

US$’000

US$’000

US$’000

US$’000

US$’000

US$’000

US$’000

Balance at December 31, 2016 ..........................

515,833,609

Share-based compensation (unaudited) .........

1,424,189

Issuance of shares reserved for share

options exercise (unaudited) ...................

1,344,551

Net loss (unaudited) ....................................

Other comprehensive income (unaudited) .....

—

—

Balance at March 31, 2017 (unaudited) .............

518,602,349

Balance at December 31, 2017 ..........................

592,072,330

Issuance of shares reserved for share

options exercise .....................................

213,018

Exercise of options ......................................

3,686,982

Third public offering, net of transaction

costs (Note II.30) ...................................

102,970,400

Share-based compensation............................

Net loss .......................................................

Other comprehensive income .......................

—

—

—

Balance at March 31, 2018................................

698,942,730

52

—

—

—

—

52

59

—

1

10

—

—

—

70

591,213

6,055

—

—

—

(946)

(237,412)

352,907

— 352,907

—

—

—

78

—

—

6,055

—

(50,623)

(50,623)

—

78

—

—

—

—

6,055

—

(50,623)

78

597,268

(868)

(288,035)

308,417

— 308,417

1,000,747

(217)

(333,446)

667,143

14,797

681,940

—

6,314

757,576

17,396

—

—

1,782,033

—

—

—

—

—

537

320

—

—

—

6,315

— 757,586

—

17,396

—

—

—

6,315

— 757,586

—

17,396

(104,596)

(104,596)

(520)

(105,116)

—

537

64

601

(438,042) 1,344,381

14,341

1,358,722

— I-12 —

